The present invention relates to a pharmaceutical composition comprising dapagliflozin or a pharmaceutically acceptable salt, hydrate, or solvate thereof; linagliptin or a pharmaceutically acceptable salt, hydrate, or solvate thereof; and an excipient, and a preparation method therefor. The pharmaceutical composition enhances a therapeutic effect on non-insulin dependent diabetes mellitus, with reduced side effects, and secure equivalent dissolution rates and non-clinical equivalence to respective agents including individual ingredients. The composition allows the minimization of tablet sizes and enhances the stability of product quality, as well, thereby improving patient's convenience for drug intake, and drug compliance. Therefore, the composition can be advantageously used as an effective prophylatic or therapeutic agent for non-insulin dependent diabetes mellitus.